International Journal of Clinical Case Reports 2024, Vol.14, No.2, 66-78 http://medscipublisher.com/index.php/ijccr 72 Human trials are crucial for assessing the safety and efficacy of SynComs in target populations. Studies have explored the use of SynComs for conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and metabolic disorders. These trials often include randomized controlled trials (RCTs) to compare SynCom interventions against placebos or standard treatments (Pirbaglou et al., 2016). 5.3 Case studies and outcomes of SynCom applications in human health The application of synthetic microbial communities (SynComs) in human health has shown promising outcomes across various studies. Here, we present detailed case studies highlighting the impact of SynComs on gut health, metabolic disorders, and mental health. Case Study 1: Gut Health and Disease Prevention In a study involving patients with irritable bowel syndrome (IBS), an engineered SynCom was introduced to modulate the gut microbiota (Figure 2). The results demonstrated significant improvement in gut barrier function and a reduction in inflammatory markers. Patients reported reduced symptoms of bloating, abdominal pain, and irregular bowel movements. The intervention led to a notable increase in beneficial bacterial populations, such as Bifidobacteriumand Lactobacillus, and a decrease in pathogenic bacteria. This study underscored the potential of SynComs to restore gut eubiosis and alleviate IBS symptoms (Baldi et al., 2021). Case Study 2: Metabolic Health Improvement A clinical trial focused on patients with type 2 diabetes (T2D) investigated the effects of SynComs on metabolic parameters. The trial involved administering a SynCom designed to enhance the gut microbiota's ability to produce short-chain fatty acids (SCFAs), which are crucial for metabolic health. Over a 12-week period, participants showed significant improvements in insulin sensitivity and reductions in fasting glucose levels. Inflammatory biomarkers such as C-reactive protein (CRP) were also reduced. These findings suggest that SynComs can play a vital role in managing T2D by modulating gut microbiota and improving metabolic outcomes (Tonucci et al., 2017). Case Study 3: Mental Health Benefits In a study exploring the gut-brain axis, SynComs were administered to patients with depression and anxiety. The engineered microbial communities were tailored to enhance the production of neurotransmitters like serotonin and gamma-aminobutyric acid (GABA). Over an 8-week intervention, patients reported significant reductions in symptoms of depression and anxiety, as measured by standardized scales. The study also observed increased levels of beneficial gut bacteria associated with mental health benefits, such as Lactobacillus andBifidobacterium. These results highlight the potential of SynComs to improve mental health by targeting the gut microbiota (Pirbaglou et al., 2016). These case studies illustrate the significant potential of SynComs to improve human health across various domains, including gut health, metabolic disorders, and mental health. Engineered SynComs can modulate the gut microbiota to achieve targeted health outcomes, making them a promising tool in personalized medicine and disease prevention. 6 Challenges and Limitations 6.1 Technical challenges in engineering and delivering SynComs Engineering synthetic microbial communities (SynComs) for enhanced probiotic functionality and gut health improvement involves several technical challenges. One significant challenge is ensuring the stability and colonization of the engineered microbes within the gut environment. The gut is a highly dynamic ecosystem, and maintaining the desired microbial composition over time can be difficult due to horizontal gene transfer and mutations (van Leeuwen et al., 2023; Martins et al., 2023). Additionally, the complexity of the gut microbiome requires precise control over microbial interactions and functions, which is not always achievable with current synthetic biology tools (Landry and Tabor, 2017; Dou and Bennett, 2018). Another technical hurdle is the delivery of these engineered SynComs to the gut. Effective delivery systems must protect the microbes from the harsh conditions of the gastrointestinal tract and ensure their release at the appropriate site (Landry and Tabor, 2017).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==